Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Frattini

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-LintuzumabTodd L Rosenblat, Michael R McDevitt, Jorge A Carrasquillo, et al.
Blood|April 20, 2010
Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemiaPeter G Maslak, Tao Dao, Lee M Krug, et al.
Leukemia Research|August 13, 2022
CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insightsNaveen Pemmaraju, Nathaniel R Wilson, Jayastu Senapati, et al.
Leukemia|April 11, 2019
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemiaDaniel A Pollyea, Martin S Tallman, Stéphane de Botton, et al.
The Lancet. Oncology|January 18, 2018
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studyCourtney D DiNardo, Keith W Pratz, Anthony Letai, et al.
The Lancet. Oncology|October 21, 2021
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trialCourtney D DiNardo, Andre C Schuh, Eytan M Stein, et al.
The Lancet. Haematology|March 9, 2020
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trialEytan M Stein, Amir T Fathi, Courtney D DiNardo, et al.
Cancer Medicine|August 24, 2021
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysisStéphane de Botton, Joseph M Brandwein, Andrew H Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2018
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent FailureAmer M Zeidan, Hanna A Knaus, Tara M Robinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid LeukemiaCourtney D DiNardo, Anthony S Stein, Eytan M Stein, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-LintuzumabTodd L Rosenblat, Michael R McDevitt, Jorge A Carrasquillo, et al.
Blood|April 20, 2010
Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemiaPeter G Maslak, Tao Dao, Lee M Krug, et al.
Leukemia Research|August 13, 2022
CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insightsNaveen Pemmaraju, Nathaniel R Wilson, Jayastu Senapati, et al.
Leukemia|April 11, 2019
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemiaDaniel A Pollyea, Martin S Tallman, Stéphane de Botton, et al.
The Lancet. Oncology|January 18, 2018
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studyCourtney D DiNardo, Keith W Pratz, Anthony Letai, et al.
The Lancet. Oncology|October 21, 2021
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trialCourtney D DiNardo, Andre C Schuh, Eytan M Stein, et al.
The Lancet. Haematology|March 9, 2020
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trialEytan M Stein, Amir T Fathi, Courtney D DiNardo, et al.
Cancer Medicine|August 24, 2021
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysisStéphane de Botton, Joseph M Brandwein, Andrew H Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2018
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent FailureAmer M Zeidan, Hanna A Knaus, Tara M Robinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid LeukemiaCourtney D DiNardo, Anthony S Stein, Eytan M Stein, et al.
Pageof 6